Search

Seven years ago, when the FDA approved the first-ever chimeric antigen receptor (CAR)-T cell therapy, Novartis' then-CEO Joseph Jimenez, MBA, said Kymriah (tisagenlecleucel) represented a 'paradigm-changing' therapy. In the years [...]

Byline: Gireesh Babu, New Delhi The National Pharmaceutical Pricing Authority (NPPA) has called for data from the manufacturers of specific forms of scheduled formulations of nicotine, used for nicotine replacement [...]

Byline: Gireesh Babu The National Pharmaceutical Pricing Authority (NPPA) has called for data from the manufacturers of specific forms of scheduled formulations of nicotine, used for nicotine replacement therapy, as [...]

Byline: Marc Lutz When it comes to health care in America, 'complicated' and 'imperfect' may best describe the nation's system of coverage. Since 1986, the rising costs of health insurance [...]

Byline: Our Bureau The National Pharmaceutical Pricing Authority (NPPA) has approved a 50 per cent increase in ceiling prices of 11 formulations of eight drugs, invoking extraordinary powers in public [...]

When I asked the shopkeeper to give me colic drops, a herbal medicine used to treat symptoms of excess gas caused by certain foods or air swallowing, I was charged [...]

https://www.economist.com/newsletters/us-in-brief to receive 'The US in brief' as a newsletter, each weekday, in your inbox. The two presidential candidates struck very different tones at events on Thursday. Kamala Harris appeared [...]

Effective Jan. 1,2021, under CMS's final outpatient prospective payment system (OPPS) final rule for CY2020, hospitals nationwide were required to publish their negotiated rates, chargemaster prices and drug prices for [...]

Objective: To compare the Medicare Part D market share of brand drugs with their net-to-list price ratio. Data Sources and Study Setting: SSR Health Brand Net Price Tool and Medical Expenditure Panel Survey, 2007-2019. Study Design: For each drug, we calculated the ratio of net to list price and the percent of users that were Medicare-eligible. We compared these cross-sectionally in each year and estimated a difference-in-differences model comparing drugs with high or low Medicare market shares (MMS) after following changes to program incentives in 2010. Data Collection/Extraction Methods: The sample included brand drugs without generic competitors appearing in both datasets. Principal Findings: Net-to-list price ratios were negatively correlated with MMS in the later years of our sample. In 2019, a 10% increase in MMS was associated with a significant 4.6% [95% CI: 2.1%, 7.1%] decrease in net-to-list ratio. Difference-in-differences showed net-to-list price ratios of drugs with above median MMS fell relative to those with below median MMS. By 2019, we observe an absolute reduction of -0.2 [95% CI: -0.29, -0.11], representing 28% reduction relative to the average ratio in 2010. Conclusions: Greater exposure to the Medicare Part D market was associated with larger differences between net and list prices of drugs. KEYWORDS donut hole, drug pricing, Medicare Part D, prescription drugs, rebates What is known on this topic * The list price of brand drugs has increased faster than post-discount 'net' prices paid by insurers. This can have important implications for cost sharing of individuals. * Medicare Part D is hypothesized to contribute to this phenomenon. What this study adds * This is the first study to examine whether drugs that disproportionately target the Medicare Part D market have systematically different list pricing than those which do not. * Drugs with a high proportion of Medicare-eligible users had higher list prices, relative to net prices, in 2018 and 2019. That difference grew from 2011 to 2019, but was not statistically significant until 2018. * We observed no relationship prior to 2010., 1 | INTRODUCTION The list price, or wholesale acquisition cost (WAC), of brand drugs has generally increased more rapidly than 'net' prices paid by insurers--a pattern reflecting the increased use [...]

Byline: Peethaambaran, Chennai The Drugs Control Administration (DCA) in Telangana has filed a case against one Himachal Pradesh based drug manufacturer under the Essential Commodities Act, 1955 for violation of [...]

The Drugs Control Administration (DCA) in Telangana has filed a case against one Himachal Pradesh based drug manufacturer under the Essential Commodities Act, 1955 for violation of Drug Price Control [...]

Twenty twenty-three was called the Year of Ozempic, though it was also a year of Ozempic backlash and Ozempic shortages, which could persist for years. Even so, we appear very [...]

Senator Bernie Sanders is set to lead a Senate investigation into the high prices charged by Novo Nordisk for its diabetes and anti-obesity medications Ozempic and Wegovy, The Financial Times' [...]

Byline: Our Bureau The Central government has clarified that based on the WPI factor of a positive growth of 0.00551%, there will be no change in the prevailing ceiling prices [...]

Byline: Our Bureau, New Delhi The National Pharmaceutical Pricing Authority (NPPA) has notified revised ceiling prices of 923 scheduled formulations with effect from April 1, 2024, in tune with the [...]

Byline: Our Bureau The National Pharmaceutical Pricing Authority (NPPA) has notified revised ceiling prices of 923 scheduled formulations with effect from April 1, 2024, in tune with the change in [...]

President Joe Biden is expected to tout his healthcare policy wins in his State of the Union address. Medicare expansion, lower drug prices, and reproductive healthcare access are some of [...]